Latest News and Press Releases

COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™...

EVX-01 induced positive clinically relevant immune responses in all assessed patientsBooster immunizations tended to increase the immune responseThe observed immune responses were mediated by both...

COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™...

Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosingFavorable safety profile confirmedTrial on track for one-year clinical efficacy readout in Q3...

Evaxion und sein Kooperationspartner testeten die von Evaxion entwickelten Impfstoff-Antigene gegen Staphylococcus aureus in einem klinisch relevanten Tiermodell für postoperative WundinfektionenDie...

Evaxion et son collaborateur ont testé les antigènes du vaccin conçus par Evaxion contre le staphylocoque doré sur un modèle animal cliniquement pertinent présentant une infection du site...

Evaxion and its collaborator tested Evaxion-designed vaccine antigens against Staphylococcus aureus in a clinically relevant animal model of surgical site infectionsThe vaccine antigens significantly...

Precision vaccine project initiated with the ambition to obtain Preclinical Proof-of-Concept by H2 2024. The novel concept entails AI-identification of a new class of cancer vaccine targets, named...

Die unternehmenseigene AI-Immunology™-Plattform bietet das Potenzial für eine neue Ära der Entdeckung, des Designs und der Entwicklung von Impfstoffen mithilfe fortschrittlicher KI- und maschineller...

La plateforme AI-Immunology™ brevetée ouvre la voie d'une nouvelle ère dans le monde de la découverte, de la conception et du développement de vaccins grâce à des technologies avancées d'IA et...